Cemadotin

Summary

Cemadotin is a synthetic analogue of the marine peptide dolastatin‑15 belonging to the antimitotic peptide class. Developed as an investigational anticancer agent, it has been evaluated in early‑phase clinical trials for solid tumours and is also used as a model cytotoxic payload in antibody‑drug conjugate (ADC) research. The compound is administered intravenously as a continuous infusion and acts by interfering with microtubule dynamics during cell division.

Mechanism of Action

Cemadotin binds directly to tubulin at a site distinct from that of vinblastine, producing two classes of binding affinity (Kd ≈ 19 µM and 136 µM). This interaction strongly suppresses microtubule dynamic instability: growth and shortening rates fall, rescue frequency rises, and microtubules spend more time in a paused state. The resulting blockade of spindle dynamics arrests cells in mitosis, accounting for its antitumor activity.

What the Research Shows

Pre‑clinical work demonstrated that cemadotin inhibits proliferation of cultured cancer cells and suppresses growth of human tumour xenografts. A biochemical study showed direct tubulin binding and a novel mechanism of microtubule dynamics suppression. Clinical experience is limited to phase I trials. One study used a 5‑day continuous intravenous infusion, establishing a maximum‑tolerated dose of 12.5 mg/m² with reversible neutropenia as the dose‑limiting toxicity and no objective responses. Another 24‑hour infusion trial identified hypertension (occasionally with cardiac ischemia signs) as dose‑limiting, with a recommended dose of 15 mg/m² for further study. No cardiovascular toxicity was observed with the longer infusion schedule. Cemadotin derivatives are also employed as model drugs for site‑specific conjugation in ADC development, illustrating its utility in drug‑delivery research.

Reported Benefits

Cemadotin shows potent antimitotic activity in vitro and in animal tumour models, attributable to a unique tubulin‑binding site that suppresses microtubule dynamics. Early clinical studies confirmed biologically active plasma concentrations and defined tolerable infusion regimens, providing a foundation for further exploration as a standalone agent or as an ADC payload.

Limitations of the Evidence

Evidence of clinical efficacy is lacking; phase I trials reported no objective tumour responses. Toxicities, notably hypertension and neutropenia, limit dose escalation and may restrict therapeutic windows. The compound remains investigational, with data confined to early‑phase studies and pre‑clinical models, and its novel binding site has not been validated in larger patient cohorts.

Safety Considerations

The principal toxicities observed are reversible neutropenia (dose‑related) and hypertension, the latter sometimes accompanied by transient cardiac ischemia signs. Cardiovascular events appear linked to peak plasma levels, as a prolonged 120‑hour infusion avoided such effects. Non‑hematologic adverse events were moderate, and overall toxicities were considered manageable but significant enough to define dose limits.

How It Is Administered

Cemadotin is administered intravenously as a continuous infusion, typically over 24 hours or 120 hours (5 days). The drug is water‑soluble, allowing infusion without special formulation requirements. In ADC research, cemadotin derivatives are chemically linked to antibodies via cleavable linkers for targeted delivery.

Routes of Administration

Goals & Uses

• Solid tumor treatmentOncologyModerate
• Hematologic malignancy treatmentOncologyLow
• Tubulin polymerization inhibitionPharmacological MechanismHigh

Contraindications

• Severe hepatic impairmentOrganHighLiver function concerns
• Cardiovascular disease / conduction disordersCardiacHigh
• Severe bone marrow suppressionHematologicModerate

Adverse Effects

• Peripheral neuropathyNeurologicalUncommon
• HypotensionCardiovascularCommonLow blood pressure
• Nausea and vomitingGastrointestinalCommon
• NeutropeniaHematologicCommonLow neutrophil count
• FatigueGeneralCommonLow energy or tiredness
• BradycardiaCardiovascularCommon

Drug Interactions

• CYP3A4 inhibitorsModerate
• Other cardiotoxic agentsHigh
• Other myelosuppressive agentsModerate

Population Constraints

• Elderly patients with cardiac comorbiditiesAge/CardiacRelative
• Pediatric patientsAgeRelative
• Pregnant or lactating womenReproductiveAbsolute

Regulatory Status

• European UnionInvestigationalEuropean clinical trials conducted (BASF/Knoll); never received EMA marketing authorization.
• United StatesInvestigationalInvestigated under IND but never approved by FDA; clinical development discontinued.

Never received regulatory approval in any jurisdiction. Development discontinued after Phase II trials showed cardiovascular toxicity (hypotension, bradycardia) and limited clinical benefit as a single agent. Served as a structural template for antibody-drug conjugate (ADC) warheads such as monomethyl auristatin E (MMAE).

Evidence & Sources

• Marine peptides and related compounds in clinical trial
  Journal ArticleModerateRawat DS, et al.2006-01-01T00:00:00.000000Z
• Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action
  Journal ArticleLowJordan MA, et al.1998-01-01T00:00:00.000000Z
• A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion
  Journal ArticleModerateSupko JG, et al.2000-01-01T00:00:00.000000Z
• Site-specific chemical modification of antibody fragments using traceless cleavable linkers
  Journal ArticleLowBernardes GJ, et al.2013-01-01T00:00:00.000000Z
• Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer. A study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Phase I Group and Arbeitsgruppe Pharmakologie in der Onkologie und Haematologie (APOH) Group of the German Cancer Society
  Journal ArticleModerateMross K, et al.1998-01-01T00:00:00.000000Z
• Molecular Dynamics simulations of Inhibitor of Apoptosis Proteins and identification of potential small molecule inhibitors
  Journal ArticleLowJayakumar J, Anishetty S2014-01-01T00:00:00.000000Z

Frequently Asked Questions